Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q2 2025 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2024 Net Income-$69.79K-$69.79KN/M vs Q2 2024 EPS Diluted$0.00$0.00N/M vs Q2 2024 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
Operating Cash Flowderived-$51,664N/M ended Feb 28, 2025 · filed Apr 14, 2025 · 45 d after period end